The Medical Journal of Tikrit University (2025) 31 (2): 202-211
DOI: http://dx.doi.org/10.25130/mjotu.31.2.22

IRAQI Academic Scientific Journals

ISSN: 1813-1638

The Medical Journal of Tikrit University

Available online at: www.mjotu.com

MJTU

The Medical Journal of Tikrit University

MRI in Brain Tumor Evaluation: A Comprehensive Review

Raad Abdalrahman Hameed [(1)]

*

Department of surgery, Radiology unit, Collage of medicine, Tikrit university, Tikrit, Iraq.

Keywords: *Magnetic Resonance Imaging (MRI), Brain Tumors, Functional Imaging, Advanced MRI Techniques, Tumor Assessment*

ARTICLE INFO

Article history:

Received 01 Jul 2025
Accepted 01 Sep 2025
Available online 31 Dec 2025

Citation:

ABSTRACT

Background: Magnetic Resonance Imaging (MRI) has emerged as a quintessential tool in the assessment and control of brain tumors due to its non-invasive nature and advanced soft-tissue assessment. This evaluation examines the modern-day applications and destiny possibilities of MRI in brain tumor evaluation. Traditional structural imaging, inclusive of T1- and T2-weighted imaging, plays a critical position in figuring out tumor place, size, and related edema, at the same time as advanced strategies offer deeper insights into tumor biology. Functional imaging modalities inclusive of Diffusion-Weighted Imaging (DWI) and Perfusion-Weighted Imaging (PWI) permit differentiation of tumor grades, identity of remedy results, and evaluation of tumor cellularity and vascularity. Magnetic Resonance Spectroscopy (MRS) enables the analysis of tumor metabolism, providing treasured records on biomarkers including choline and lactate. Emerging techniques like Chemical Exchange Saturation Transfer (CEST) MRI are being advanced for extra precise molecular and metabolic characterization. Future advancements encompass the mixing of synthetic intelligence (AI) for computerized tumor detection, category, and prediction of healing responses. AI models blended with radiomic evaluation hold promise for customized treatment strategies. Intraoperative MRI has more desirable surgical effects by using allowing actual-time imaging, enhancing tumor resection accuracy, and retaining healthy tissue. Furthermore, extremely-high-area MRI (7T) gives extraordinary spatial and contrast decision, facilitating particular evaluation of tumor microenvironments. Despite its transformative effect, challenges continue to be, inclusive of excessive charges, accessibility problems, and interpretation variability. The aim of this review is to explore the current and future advancements in MRI technology for brain tumor evaluation, highlighting the integration of AI, advanced imaging techniques, and intraoperative MRI to improve tumor detection, treatment planning, and surgical outcomes. It also addresses challenges such as cost, accessibility, and interpretation variability.

Corresponding author E mail:
Raad.A.hameed@tu.edu.iq

INTRODUCTION

Brain tumors are most of the maximum difficult neurological situations, requiring unique diagnostic, therapeutic, and tracking strategies to enhance patient outcomes. These tumors showcase a wide spectrum of scientific, histological, and molecular traits, making their control complicated and multidisciplinary [1]. Magnetic Resonance Imaging (MRI) has emerged as the cornerstone inside the assessment of brain tumors, imparting extraordinary capabilities for both anatomical and practical evaluation. As a non-invasive imaging modality, MRI gives incredible tender-tissue contrast, enabling clinicians to discover, localize, and represent brain tumors with excessive accuracy [2].

Traditional MRI strategies, including T1-weighted and T2-weighted imaging, continue to be fundamental for identifying the anatomical information of brain tumors. These modalities assist in comparing tumor size, vicinity, and related edema, which can be crucial for preliminary analysis and surgical making plans. Furthermore, fluid-attenuated inversion healing (FLAIR) imaging complements the visualization of peritumoral edema and infiltrative margins, in particular in gliomas, in which correct delineation of tumor obstacles is vital [3].

Beyond structural imaging, improvements in MRI generation have paved the manner for functional and metabolic tests of brain tumors. Techniques like diffusion-weighted imaging (DWI) provide insights into tumor cellularity, permitting differentiation among high-grade and coffee-grade tumors. Perfusion-weighted imaging (PWI) is instrumental in assessing tumor vascularity, imparting crucial information approximately angiogenesis—a hallmark of malignancy. Magnetic Resonance Spectroscopy (MRS) has further increased the function of MRI via enabling the non-invasive evaluation of tumor metabolism, identifying biomarkers together with choline, creatine, and lactate which can be indicative of malignancy and tumor development [4].

Emerging MRI technologies, consisting of arterial spin labeling (ASL) and dynamic susceptibility assessment (DSC) imaging, have similarly improved the diagnostic application of MRI. These techniques offer distinctive information approximately cerebral blood flow and perfusion, aiding in tumor grading and remedy response evaluation. Additionally, chemical exchange saturation switch (CEST) imaging and different molecular imaging techniques are being explored for their capacity to offer real-time insights into tumor biology [5].

Despite its enormous benefits, using MRI in brain tumor assessment faces challenges along with excessive prices, constrained accessibility in low-useful resource settings, and the want for knowledge in interpretation [6]. However, with the integration of synthetic intelligence (AI) and device gaining knowledge of algorithms, the future of MRI in brain tumor assessment appears promising. AI-pushed equipment are being evolved to automate tumor detection, segmentation, and class, fostering personalized treatment techniques [7]. In precis, MRI has converted the sector of neuro-oncology by way of offering complete insights into the structural, practical, and molecular factors of brain tumors. As technology keeps to evolve, the role of MRI is set to expand in addition, making it an imperative device within the quest for improved analysis and control of brain tumors.

Current Applications of MRI in Brain Tumor Assessment

Magnetic Resonance Imaging (MRI) plays a crucial role inside the assessment of brain tumors, providing specified pics that help in diagnosis, remedy making plans, and tracking of tumor progression. MRI is mainly useful because of its excessive resolution and potential to differentiate between extraordinary sorts of tissues, making it valuable in detecting brain tumors, assessing their length, region, and effect on surrounding systems [8]. One of the primary packages of MRI in brain tumor evaluation is in the initial diagnosis and localization of the tumor. MRI can offer super snap shots that assist distinguish between benign and malignant tumors based on their traits, together with shape, comparison enhancement, and surrounding tissue involvement. This permits clinicians to decide the exact vicinity of the tumor within the brain, which is important for treatment planning, specially whilst considering surgical operation or radiation remedy [9].

Additionally, MRI techniques inclusive of useful MRI (fMRI) are used to map areas of the brain involved in critical features like speech, motor manipulate, and sensory belief. This is mainly useful in making plans surgical procedure for brain tumors placed near or within purposeful areas of the brain, assisting surgeons keep away from damaging vital areas [10]. Diffusion Tensor Imaging (DTI), a specialised MRI method, is some other vital tool in assessing brain tumors. DTI presents special pictures of white remember pathways, assisting clinicians check the tumor's impact on surrounding brain structures and aiding in surgical planning to minimize harm to healthful tissue [11].

Moreover, assessment-more desirable MRI is extensively used to evaluate the tumor's blood supply. By using an assessment agent, MRI can highlight regions of tumor vascularity, which may be beneficial for differentiating between tumor kinds, assessing tumor grade, and evaluating the reaction to treatment. This is specially treasured in monitoring tumor development or regression in the course of and after healing procedures consisting of chemotherapy or radiation [12].

Lastly, MRI spectroscopy is an extra advanced technique that could provide biochemical statistics about the tumor. By studying the chemical composition of the tumor tissue, MRI spectroscopy can assist in identifying the tumor's nature (benign vs. Malignant) and potentially offer insights into its aggressiveness or response to remedy [13]. In precis, MRI is a vital device in the diagnosis, remedy making plans, and monitoring of brain tumors. It permits for precise visualization of the tumor, its dating with surrounding systems, and provides important statistics that courses clinical decisions and improves affected person consequences.

Brain Tumors and their Stages and Grades

Brain tumors are ordinary growths of cells inside the brain or primary nervous gadget (CNS). They may be labeled into two foremost kinds: number one and secondary tumors [14]. Primary brain tumors originate in the brain, inclusive of gliomas or meningiomas, even as secondary or metastatic brain tumors occur whilst most cancers from some other a part of the frame spreads to the brain, which includes lung or breast cancer. These tumors are similarly categorized as benign or malignant. Benign tumors, like meningiomas, are non-cancerous however can nonetheless cause giant symptoms because of their stress on adjoining tissues. Malignant tumors, together with glioblastoma multiforme, are cancerous, competitive, and lifestyles-threatening due to their invasive nature [15].

Brain tumors are fantastically various, with a number of the maximum not unusual sorts which include gliomas, which stand up from glial cells and embody astrocytoma, oligodendrogliomas, and glioblastomas. Meningiomas, then again, are usually benign and get up from the meninges, the protective layers surrounding the brain. Pituitary adenomas have an effect on the pituitary gland, disrupting hormone law, even as metastatic tumors are regularly extra commonplace than primary brain tumors and reflect advanced systemic cancer. Each type presents precise diagnostic and therapeutic demanding situations, requiring tailored methods [16].

The development of brain tumors is normally described by means of their grade, as classified with the aid of the World Health Organization (WHO). Grade I tumors, like pilocytic astrocytoma, are gradual-developing and regularly treatable with surgical procedure [17]. Grade II tumors display extra infiltrative dispositions however continue to be especially gradual-developing. Grade III tumors, along with anaplastic astrocytoma, are more competitive, with a higher rate of recurrence. Grade IV tumors, along with glioblastoma multiforme, are the maximum competitive and invasive, with a bad analysis no matter superior remedy alternatives [18].

Diagnosing brain tumors involves a combination of clinical assessment, imaging, and histopathological confirmation. Imaging techniques, especially magnetic resonance imaging (MRI), are the cornerstone of brain tumor diagnosis. MRI presents superior gentle-tissue evaluation, helping delineate tumor barriers and determine characteristics inclusive of edema and necrosis. Advanced MRI modalities like diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI) can determine tumor cellularity and vascularity. Computed tomography (CT) scans are beneficial for detecting calcifications or hemorrhages inside tumors and are regularly hired in emergency settings for rapid evaluation. Histological exam following biopsy or surgical resection stays essential for definitive prognosis and grading [19].

Treatment strategies for brain tumors rely upon the type, grade, and region of the tumor, as well as the patient's universal health. Surgical resection is regularly step one, aiming for maximum tumor removal whilst preserving neurological feature. Radiation therapy, including stereotactic radiosurgery, is usually used for malignant and inoperable tumors. Chemotherapy, the usage of dealers like temozolomide, performs a position in systemic treatment, especially for high-grade gliomas. Emerging remedies, inclusive of targeted therapy, immunotherapy, and tumor-treating fields (TTFs), are being explored to improve consequences [20].

MRI-Based Diagnosis of Brain Tumor Types

1- Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme is the most competitive and common primary brain tumor in adults. On MRI, GBM commonly gives as a heterogeneously enhancing mass on T1-weighted imaging with gadolinium contrast [21]. The tumor frequently has a necrotic core surrounded through abnormal enhancement, indicative of its invasive nature. Peritumoral edema seems as hyperintense on T2-weighted and FLAIR sequences, reflecting vasogenic edema extending into the encompassing brain parenchyma. Advanced techniques like Diffusion-Weighted Imaging (DWI) and Perfusion-Weighted Imaging (PWI) further spotlight regions of restricted diffusion and expanded perfusion, respectively, that are hallmark capabilities of malignancy [22]. (Figure1).

2- Meningioma

Meningiomas are extra-axial, typically benign tumors arising from the meninges. On T1-weighted MRI with contrast, they appear as well-defined, homogeneously enhancing masses. A characteristic “Dural tail sign” is often present, indicating the tumor's attachment to the meninges. These tumors rarely infiltrate the brain but can cause significant mass effect and compression. Meningiomas may show calcifications on CT, which appear hypointense on T2-weighted MRI. Their predictability in growth patterns makes them relatively easy to diagnose with imaging alone [23].

3- Pituitary Adenoma

Pituitary adenomas are common tumors of the sellar region, classified as microadenomas (<10 mm) or macroadenomas (≥10 mm). On coronal T1-weighted MRI with contrast, these tumors exhibit homogeneous enhancement, though larger lesions may appear heterogeneously enhancing due to hemorrhage or cystic degeneration. The tumors often compress the optic chiasm, causing visual disturbances. MRI is crucial in assessing tumor size, extension into the cavernous sinus, and effects on nearby structures, which aids in surgical planning (Figure 3) [24].

4- Metastatic Brain Tumors

Metastatic brain tumors are secondary lesions resulting from systemic cancer spread. MRI reveals multiple ring-enhancing lesions on T1-weighted imaging with gadolinium, surrounded by significant vasogenic edema visible on T2-weighted images. These tumors often localize at the gray-white matter junction due to their reliance on blood supply [25]. Advanced MRI techniques, such as PWI and MR spectroscopy, are essential for differentiating metastases from primary brain tumors, as they often exhibit high perfusion and distinct metabolic profiles (Figure 4) [26].

5- Low-Grade Gliomas

Low-grade gliomas, including astrocytoma’s and oligodendrogliomas, exhibit subtle and diffuse growth patterns. On T2-weighted MRI, these tumors appear hyperintense with minimal or no contrast enhancement on T1-weighted imaging, reflecting their lower aggressiveness. However, advanced imaging techniques such as MR spectroscopy can reveal elevated metabolites like choline, indicative of tumor activity. Regular imaging follow-up is crucial to monitor malignant transformation, often marked by the development of contrast enhancement (Figure 5) [27].

Conclusion

In conclusion, MRI remains a cornerstone in the assessment of brain tumors, offering unheard of advantages in phrases of imaging resolution, non-invasive strategies, and the capability to evaluate tumor characteristics in detail. Current programs which include structural MRI, practical MRI (fMRI), diffusion tensor imaging (DTI), evaluation-better MRI, and MRI spectroscopy offer vital insights into tumor vicinity, type, and impact on surrounding brain structures. These technologies have drastically improved the accuracy of brain tumor prognosis, treatment making plans, and monitoring. Looking ahead, the future of MRI in brain tumor assessment holds even more promise with advancements in imaging strategies, such as molecular imaging and artificial intelligence integration, which may also enhance early detection, are expecting remedy results, and offer customized remedy techniques. However, challenges continue to be, consisting of the want for improved imaging biomarkers and standardization of protocols throughout distinct scientific settings. Despite these challenges, MRI's role in brain tumor management is predicted to retain evolving, providing better results and a deeper expertise of brain tumor biology.

Challenges and Limitations

Despite improvements, MRI faces challenges consisting of: Cost and Accessibility: High charges limit vast use in useful resource-limited settings. Interpretation Variability: Requires knowledge for accurate interpretation. Gadolinium Concerns: Long-term consequences of gadolinium-primarily based contrast agents stay an issue, riding research toward alternative strategies.

References

1. Wu Y, Wood TC, Derks SHA, Pruis IJ, van der Voort S, van Zanten SEMV, et al. Reproducibility of APT-weighted CEST-MRI at 3T in healthy brain and tumor across sessions and scanners. Sci Rep. 2023;13(1):18115. doi: 10.1038/s41598-023-44891-0. Available from: https://doi.org/10.1038/s41598-023-44891-0

2. Bhangale PN, Kashikar SV, Kasat PR, Shrivastava P, Kumari A. A comprehensive review on the role of MRI in the assessment of supratentorial neoplasms: Comparative insights into adult and pediatric cases. Cureus. 2024;16(8):e67553. doi: 10.7759/cureus.67553. Available from: https://doi.org/10.7759/cureus.67553

3. Artzi M, Liberman G, Nadav G, Blumenthal DT, Bokstein F, Aizenstein O, et al. Optimization of DCE-MRI protocol for the assessment of patients with brain tumors. Magn Reson Imaging. 2016;34(9):1242-7. doi: 10.1016/j.mri.2016.07.003. Available from: https://doi.org/10.1016/j.mri.2016.07.003

4. Dou W, Lin CE, Ding H, Shen Y, Dou C, Qian L, et al. Chemical exchange saturation transfer magnetic resonance imaging and its main and potential applications in pre-clinical and clinical studies. Quant Imaging Med Surg. 2019;9(10):1747-66. doi: 10.21037/qims.2019.10.03. Available from: https://doi.org/10.21037/qims.2019.10.03

5. Hakyemez B, Erdogan C, Bolca N, et al. Evaluation of different cerebral mass lesions by perfusion-weighted MR imaging. J Magn Reson Imaging. 2006;24:817-24. doi:

10.1002/jmri.20628. Available from: https://doi.org/10.1002/jmri.20628

6. Zheng B, Zhao Z, Zheng P, Liu Q, Li S, Jiang X, et al. The current state of MRI-based radiomics in pituitary adenoma: promising but challenging. Front Endocrinol (Lausanne). 2024;15:1426781. doi: 10.3389/fendo.2024.1426781. Available from: https://doi.org/10.3389/fendo.2024.1426781

7. Filss CP, Cramer J, Löher S, Lohmann P, Stoffels G, Stegmayr C, et al. Assessment of brain tumour perfusion using early-phase 18F-FET PET: Comparison with perfusion-weighted MRI. Mol Imaging Biol. 2024;26(1):36-44. doi: 10.1007/s11307-023-01861-2. Available from: https://doi.org/10.1007/s11307-023-01861-2

8. Nelson SJ. Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. NMR Biomed. 2011;24(6):734-49. doi: 10.1002/nbm.1669. Available from: https://doi.org/10.1002/nbm.1669

9. Khadhraoui E, Schmidt L, Klebingat S, Schwab R, Hernández-Durán S, Gihr G, et al. Comparison of a new MR rapid wash-out map with MR perfusion in brain tumors. BMC Cancer. 2024;24(1):1139. doi: 10.1186/s12885-024-12909-z. Available from: https://doi.org/10.1186/s12885-024-12909-z

10. Prysiazhniuk Y, Server A, Leske H, Bech-Aase Ø, Helseth E, Eijgelaar RS, et al. Diffuse glioma molecular profiling with arterial spin labeling and dynamic susceptibility contrast perfusion MRI: A comparative study. Neuro-Oncol Adv. 2024;6(1):vdae113. doi: 10.1093/noajnl/vdae113. Available from: https://doi.org/10.1093/noajnl/vdae113

11. Gupta A, Thai A, Steenerson KK, Alyono J. Utility of MRI in the outpatient evaluation of patients with chronic continuous or recurrent dizziness. Otolaryngol Head Neck Surg. 2024;45(8):919-24. doi: 10.1097/MAO.0000000000004269. Available from: https://doi.org/10.1097/MAO.0000000000004269

12. Kanaly CW, Ding D, Mehta AI, Waller AF, Crocker I, Desjardins A, et al. A novel method for volumetric MRI response assessment of enhancing brain tumors. PLoS One. 2011;6(1):e16031. doi: 10.1371/journal.pone.0016031. Available from: https://doi.org/10.1371/journal.pone.0016031

13. Liu F, Yao Y, Zhu B, Yu Y, Ren R, Hu Y. The novel imaging methods in diagnosis and assessment of cerebrovascular diseases: An overview. Front Med (Lausanne). 2024;11:1269742. doi: 10.3389/fmed.2024.1269742. Available from: https://doi.org/10.3389/fmed.2024.1269742

14. Kılıç AE, Yaltırık Bilgin E, Ünal Ö. Metastases and primary brain tumors affecting the fornix of the brain. Cureus. 2024;16(4):e57612. doi: 10.7759/cureus.57612. Available from: https://doi.org/10.7759/cureus.57612

15. Shih RY, Smirniotopoulos JG. Posterior fossa tumors in adult patients. Neuroimaging Clin N Am. 2016;26:493-510. doi: 10.1016/j.nic.2016.06.003. Available from: https://doi.org/10.1016/j.nic.2016.06.003

16. Martín-Noguerol T, Mohan S, Santos-Armentia E, Cabrera-Zubizarreta A, Luna A. Advanced MRI assessment of non-enhancing peritumoral signal abnormality in brain lesions. Eur J Radiol. 2021;143:109900. doi: 10.1016/j.ejrad.2021.109900. Available from: https://doi.org/10.1016/j.ejrad.2021.109900

17. Moshe YH, Buchsweiler Y, Teicher M, Artzi M. Handling missing MRI data in brain tumors classification tasks: Usage of synthetic images vs. duplicate images and empty images. J Magn Reson Imaging. 2024;60(2):561-73. doi: 10.1002/jmri.29072. Available from: https://doi.org/10.1002/jmri.29072

18. Asfaw ZK, Young T, Brown C, Germano IM. Charting the success of neuronavigation in brain tumor surgery: From inception to adoption and evolution. J Neurooncol. 2024;170(1):1-10. doi: 10.1007/s11060-024-04778-0. Available from: https://doi.org/10.1007/s11060-024-04778-0

19. Pons-Escoda A, Garcia-Ruiz A, Garcia-Hidalgo C, Gil-Solsona R, Naval-Baudin P, Martin-Noguerol T, et al. MR dynamic-susceptibility-contrast perfusion metrics in the presurgical discrimination of adult solitary intra-axial cerebellar tumors. Eur Radiol. 2023;33(12):9120-9. doi: 10.1007/s00330-023-09892-7. Available from: https://doi.org/10.1007/s00330-023-09892-7

20. Kaufmann TJ, Smits M, Boxerman J, et al. Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro-Oncology. 2020;22:757-72. doi: 10.1093/neuonc/noaa030. Available from: https://doi.org/10.1093/neuonc/noaa030

21. Wang Z, Wang B, Li Z, Han G, Meng C, Jiao B, et al. The consistency of dynamic contrast-enhanced MRI and filter-exchange imaging in measuring water exchange across the blood-brain barrier in high-grade glioma. J Magn Reson Imaging. 2023;58(6):1850-60. doi: 10.1002/jmri.28729. Available from: https://doi.org/10.1002/jmri.28729

22. Hatch, E. E., Linet, M. S., Zhang, J., Fine, H. A., Shapiro, W. R., Selker, R. G., Black, P. M., & Inskip, P. D. (2005). Reproductive and hormonal factors and risk of brain tumors in adult females. *International Journal of Cancer, 114*(5), 797-805. https://doi.org/10.1002/ijc.20776

23. Buerki, R. A., Horbinski, C. M., Kruser, T., Horowitz, P. M., James, C. D., & Lukas, R. V. (2018). An overview of meningiomas. *Future Oncology, 14*(21), 2161-2177. https://doi.org/10.2217/fon-2018-0006

24. Daly, A. F., & Beckers, A. (2020). The epidemiology of pituitary adenomas. *Endocrinology and Metabolism Clinics*

of North America, 49(3), 347-355. https://doi.org/10.1016/j.ecl.2020.04.002

25. Boire, A., Brastianos, P. K., Garzia, L., & Valiente, M. (2020). Brain metastasis. *Nature Reviews Cancer, 20*(1), 4-11. https://doi.org/10.1038/s41568-019-0220-y

26. Gonzalez, H., Mei, W., Robles, I., Hagerling, C., Allen, B. M., Hauge Okholm, T. L., Nanjaraj, A., Verbeek, T., Kalavacherla, S., van Gogh, M., Georgiou, S., Daras, M., Phillips, J. J., Spitzer, M. H., Roose, J. P., & Werb, Z. (2022). Cellular architecture of human brain metastases. *Cell, 185*(4), 729-745.e20. https://doi.org/10.1016/j.cell.2021.12.043

27. Bhatia, A., Moreno, R., Reiner, A. S., Nandakumar, S., Walch, H. S., Thomas, T. M., Nicklin, P. J., Choi, Y., Skakodub, A., Malani, R., Prabhakaran, V., Tiwari, P., Diaz, M., Panageas, K. S., Mellinghoff, I. K., Bale, T. A., & Young, R. J. (2024). Tumor volume growth rates and doubling times during active surveillance of IDH-mutant low-grade glioma. *Clinical Cancer Research, 30*(1), 106-115. https://doi.org/10.1158/1078-0432.CCR-23-1180

FIGURES



Figure 1: Glioblastoma multiforme (GBM) (A) a post-contrast T1-weighted image, (B) an ADC map, (C) a CBV map, (D) a perfusion signal intensity time curve.



Figure 2: Extra axial well-circumscribed, hemispheric, homogeneous mass, isointense with gray matter on T1W images, also isointense on T2W images and with intense, homogeneous enhancement after intravenous gadolinium injection



Figure 3: Pituitary Adenoma



Figure 4: Metastatic Brain Tumors



Figure 5: Patient with a low-grade glioma showing contrast enhancement, microvascular leakage (MVL), and a high perfusion estimate. a Transaxial FLAIR-weighted image; b MT-weighted image after administration of intravenous Gd-DTPA demonstrates a mass with a focus of enhancement; c gradient-echo axial image with color overlay map showing the area of MVL; d corresponding perfusion map with a high rCBV value of 2.92. Patient relapsed 5 months after treatment.